{
    "clinical_study": {
        "@rank": "20089", 
        "arm_group": [
            {
                "arm_group_label": "Lobeglitazone", 
                "arm_group_type": "Experimental", 
                "description": "Subjects received Lobeglitazone 0.5 mg daily for 12 days in one period and in the other period, Subjects don't receive Lobeglitazone."
            }, 
            {
                "arm_group_label": "Warfarin", 
                "arm_group_type": "Experimental", 
                "description": "Subjects received Warfarin 25 mg once at period 1 and 2."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate a pharmacokinetic drug interaction between\n      lobeglitazone and warfarin in healthy subjects."
        }, 
        "brief_title": "Drug-drug Interaction Study(Lobeglitazone, Warfarin)", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "From day 1 to day 12, lobeglitazone 0.5mg is administered daily to Group 1 subjects during\n      period 1. Then on day 5,warfarin 25mg is co-administered Group 1 subjects at period 1. After\n      10 day-break, warfarin 25mg is administered Group 1 subjects at period 2. On period 2,\n      lobeglitazone is not administered.\n\n      Group 2 is administered in reverse order."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A healthy male volunteer between 19 and 55 years old.\n\n          -  BMI between 19 and 27.\n\n          -  Signed the informed consent form prior to study participation.\n\n          -  Able to participate in the entire trial\n\n        Exclusion Criteria:\n\n          -  Clinically significant hepatic, renal, digestive system, respiratory system,\n             endocrine system, nervous system, hematologic, cardiovascular system, tumor or have\n             history of tumor\n\n          -  Clinically significant hemorrhagic disease\n\n          -  Genetic problems such as galactose intolerance, Lapp lactase deficiency,\n             glucose-galactose malabsorption\n\n          -  Have hypersensitivity reactions history for lobeglitazone, warfarin, excipient of IP\n             or aspirin, antibiotics\n\n          -  Medication which might significantly alter the absorption, distribution, metabolism,\n             or excretion of investigational products within 30 days prior to screening\n\n          -  Participated in the other clinical trials and administrated IP within 60 days prior\n             to screening\n\n          -  Subject takes ethical drug or herbal medicine within 14 days, OTC within 7 days\n             before screening\n\n          -  Previously donate whole blood within 60 days or component blood within 30 days\n\n          -  sit SBP < 90mmHg or sit SBP \u2265 140mmHg or sit DBP < 60mmHg or sit DBP \u2265 90mmHg\n\n          -  A heavy alcohol consumer (alcohol > 140 g/week) or cannot stop drinking\n\n          -  A heavy smoker (cigarette > 10 cigarettes per day) or cannot stop smoking\n\n          -  A heavy caffeine consumer (more than 4cups per a day) or A heavy grapefruit consumer\n             (more than 1cup per a day) or cannot stop having\n\n          -  Positive for the Triage TOX drug on urine\n\n          -  Positive for HIV antibody, HBsAg, HCV antibody test\n\n          -  AST, ALT or Total bilirubin > UNL * 1.5\n\n          -  Estimated GFR < normal limit\n\n          -  INR, aPTT over the normal limit\n\n          -  Clinically significant laboratory test result\n\n          -  Clinically significant ECG\n\n          -  An impossible one who participates in clinical trial by investigator's decision\n             including other reason"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002611", 
            "org_study_id": "19DDI13016"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lobeglitazone", 
                "intervention_name": "Lobeglitazone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Warfarin", 
                "intervention_name": "Warfarin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Warfarin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lobeglitazone", 
            "Warfarin", 
            "Type 2 Diabetes Mellitus", 
            "Drug-Drug interaction", 
            "Phase 1"
        ], 
        "lastchanged_date": "December 1, 2013", 
        "location": {
            "contact": {
                "email": "jw0701.ko@samsung.com", 
                "last_name": "Jae Wook Ko, M.D., Ph.D.", 
                "phone": "82-2-3410-3690"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open Label, Randomized, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Lobeglitazone and Warfarin in Healthy Subjects", 
        "overall_contact": {
            "email": "jw0701.ko@samsung.com", 
            "last_name": "Jae Wook Ko, M.D., Ph.D.", 
            "phone": "82-2-3410-3690"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Jae Wook Ko, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Assess AUC of lobeglitazone", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h"
            }, 
            {
                "measure": "Assess Cmax  of lobeglitazone", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h"
            }, 
            {
                "measure": "Assess AUC of S-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }, 
            {
                "measure": "Assess Cmax of S-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }, 
            {
                "measure": "Assess AUC of R-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }, 
            {
                "measure": "Assess Cmax of R-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002611"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assess tmax of lobeglitazone", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h"
            }, 
            {
                "measure": "Assess t1/2 of lobeglitazone", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h"
            }, 
            {
                "measure": "Assess CL/F of lobeglitazone", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h"
            }, 
            {
                "measure": "Assess Vd/F of lobeglitazone", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h"
            }, 
            {
                "measure": "Assess tmax of S-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }, 
            {
                "measure": "Assess t1/2 of S-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }, 
            {
                "measure": "Assess CL/F of S-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }, 
            {
                "measure": "Assess Vd/F of S-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }, 
            {
                "measure": "Assess tmax of R-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }, 
            {
                "measure": "Assess t1/2 of R-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }, 
            {
                "measure": "Assess CL/F of R-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }, 
            {
                "measure": "Assess Vd/F of R-warfarin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}